المصدر: Klhsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmrer M, Gabruswz K, Anderson NR, Petty NE, Cumms KD, Shen F, Shan X, Vel K, Blouch K, Yasho-OhtanY, Kendern SS, K MY, O'Connor RS, Wallace SR, KozlowskMS, Marchne DM, Shestov M, Garc BA, June CH, Gl S. Human cher anten receptor macrophages for cancer munotherapy. Nat Btechnol. 2020 Aug;38(8):947-953. do 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04660929Test

المصدر: A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04650451Test

المصدر: A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04464967Test

المصدر: INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02205047Test